MANE logo

MANE
Veradermics Inc

169
Mkt Cap
$3.74B
Volume
2,280.00
52W High
$101.81
52W Low
$17.00
Price
$100.10
MANE Fundamentals
Prev Close
$67.84
Open
$81.07
50D MA
$59.01
Beta
0.00
Avg. Volume
426,864.42
EPS (Annual)
-$2.23
P/B
-30.89
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Veradermics Announces Launch of Public Offering
Veradermics, Incorporated (Veradermics) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...
Business Wire·14h ago
News Placeholder
More News
News Placeholder
Veradermics says its hair loss pill passed a late-stage trial, potentially the first oral treatment approved in 30 years
The extended-release minoxidil tablet could be the first FDA-approved oral treatment for pattern hair loss in about 30 years...
Quartz·19h ago
News Placeholder
Futures Flat At All Time Highs Ahead Of Huge Week, Semis Set For 19th Day Of Gains
false
Zero Hedge·23h ago
News Placeholder
Veradermics Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 302 Clinical Trial in Male Pattern Hair Loss
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive...
Business Wire·1d ago
News Placeholder
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 302 Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host...
Business Wire·2d ago
News Placeholder
MANE (NYSE:MANE) Receives Average Rating of "Moderate Buy" from Analysts
Shares of MANE (NYSE:MANE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the firm, Marketbeat reports. One research...
MarketBeat·4d ago
News Placeholder
MANE (NYSE:MANE) Price Target Raised to $90.00
Leerink Partners increased their price target on MANE from $75.00 to $90.00 and gave the stock an "outperform" rating in a research report on Wednesday...
MarketBeat·6d ago
News Placeholder
Squawk Pod: OpenAI's eye-popping raise & hair today, hair forever - 04/01/26 Audio Only
OpenAI has closed a $122 billion funding round, bringing its valuation to $852 billion. Investor Cathie Wood discusses her bets on AI and the future of tech investing. Nike reported a struggle in the...
CNBC Television-YouTube·27d ago
News Placeholder
Veradermics Stock Falls 8% After Reporting Wider Loss In Q4, FY25
(RTTNews) - Shares of Veradermics, Incorporated (MANE) are moving down about 8 percent on Monday morning trading after reporting a wider loss in the fourth quarter and full year financial results...
Nasdaq News: Markets·29d ago
News Placeholder
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological...
Business Wire·29d ago
<
1
2
...
>

Latest MANE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.